To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Bisoprolol
Bisoprolol is a drug belonging to the group of beta blockers, a class of drugs used primarily in cardiovascular diseases. More specifically, it is a selective type β1 adrenergic receptor blocker [1]. Additional recommended knowledge
Pharmacology and biochemistryβ1 SelectivityIn comparison with other β1-selective β-blockers (atenolol, metoprolol, betaxolol) Bisoprolol proved to be the compound with the highest β1-selectivity in all in vitro and in vivo experiments and in all animal species investigated[2][3][4][5][6][7][8][9][10][11]
Antihypertensive effectBisoprolol had an antihypertensive effect in all hypertension models investigated. Bisoprolol reduced the blood pressure in conscious dogs with renal hypertension, accompanied by only a slight decrease in heart rate. In comparison with bisoprolol, propranolol had a weaker antihypertensive effect even at a considerably higher dose level [12]. Bisoprolol also reduced the blood pressure in rats with renal hypertension. In rats with spontaneous hypertension, the development of high blood pressure could be clearly reduced by chronic treatment with 7.5mg/ kg bisoprolol [13]. CardioprotectionMyocardial ischaemia was induced by coronary occlusion in anaesthetised open-chest dogs. The changes in the epicardial ECG typical of myocardial hypoxia (ST segment elevation) were attenuated by bisoprolol. A dose of 4 μg bisoprolol per kg i.v. inhibited the ST segment elevation, induced by coronary occlusion, by 60%. This cardioprotective effect of bisoprolol was still present 40 minutes after injection [14].
Renin-angiotensin systemBisoprolol inhibits basal and stimulated renin secretion. The release of renin was inhibited by about 65% and tachycardia by about 35% [15]. Duration of actionBisoprolol has a long duration of action. The duration of action of bisoprolol was investigated in anaesthetised guinea pigs after i.v. administration; the inhibition of isoprenaline-induced tachycardia was measured at various times after the administration of the b-blocker. The drop in the action duration curve was flatter for bisoprolol than for propranolol [16]. The results indicate a long duration of action for bisoprolol. Pharmacology of side-effectsThe performed animal experimental investigations indicated for bisoprolol no unexpected or serious side-effects. Even at high doses [30 and 100mg/ kg, single oral administration (rats)], the sedative effects ascribed to b-blockers are less marked with bisoprolol than, for instance, with propranolol. Glucose tolerance was investigated in rats and was only slightly reduced at very high doses of bisoprolol, whereas it was considerably reduced with comparable doses of propranolol [17]. Bisoprolol did not influence the lipid metabolism of adult normolipemic rats after repeated administration nor was there any quantitative change in the serum lipoprotein pattern in young hyperlipemic rats with increased plasma cholesterol and decreased alpha-lipoprotein. PharmacokineticsBioavailabilityThe bioavailability of bisoprolol from film-coated tablets is about 90%. DistributionOnly 30% of the bisoprolol in the blood is bound to plasma proteins [18] Metabolisation and excretionBisoprolol is removed from the plasma via two equally effective routes of clearance – half of the dose is metabolised to inactive metabolites in the liver and the other half is excreted as the unchanged substance via the kidneys.
Elimination half-lifeBisoprolol is removed from the plasma with a half-life of 10-12 hours [19] IndicationsBisoprolol (Concor[20], Zebeta[21], Concore[22], Monocor[23]) can be used to treat cardiovascular diseases such as hypertension, coronary heart disease, arrhythmias, ischemic heart diseases and treatment of myocardial infarction after the acute event. Patients with compensated congestive heart failure may be treated with Bisoprolol as a comedication (usually together with an ACE inhibitor, a diuretic and a digitalis-glycosid, if indicated). In patients with congestive heart failure, it reduces the need for and the consumption of oxygen of the heart muscle. It is very important to start with low doses, as bisoprolol reduces also the muscular power of the heart, which is an undesired effect in congestive heart failure. The drug is also used to treat other conditions, including dysautonomia, anxiety and hyperthyroidism (overfunction of the thyroid gland). Bisoprolol will give a positive result in doping tests. [24] References
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Bisoprolol". A list of authors is available in Wikipedia. |